Neuberger Berman Group LLC Arcutis Biotherapeutics, Inc. Transaction History

Neuberger Berman Group LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$7.51 - $15.0 $441,820 - $882,465	58,831 Added 32.15%	241,846 $2.3 Million
Q1 2023 May 12, 2023	BUY	$10.23 - $17.14 $170,196 - $285,158	16,637 Added 10.0%	183,015 $2.01 Million
Q4 2022 Feb 13, 2023	BUY	$13.96 - $20.4 $480,210 - $701,739	34,399 Added 26.06%	166,378 $2.46 Million
Q3 2022 Nov 15, 2022	SELL	$17.85 - $26.95 $84,698 - $127,877	-4,745 Reduced 3.47%	131,979 $2.52 Million
Q2 2022 Aug 15, 2022	BUY	$16.33 - $22.2 $121,625 - $165,345	7,448 Added 5.76%	136,724 $2.91 Million

Q1 2022 May 13, 2022	BUY	$14.38 - $22.79 $103,234 - $163,609	7,179 Added 5.88%	129,276 $2.49 Million
Q4 2021 Feb 11, 2022	BUY	$14.98 - $25.5 $149 - $255	10 Added 0.01%	122,097 $2.53 Million
Q3 2021 Nov 12, 2021	BUY	$19.28 - $27.1 $16,792 - $23,604	871 Added 0.72%	122,087 $2.92 Million
Q2 2021 Aug 13, 2021	BUY	$24.42 - $34.75 $37,753 - $53,723	1,546 Added 1.29%	121,216 $3.3 Million
Q1 2021 May 13, 2021	BUY	$24.47 - $36.98 $2.93 Million - $4.43 Million	119,670 New	119,670 $3.46 Million

172

126M

498K

1.64M

Ticker ARQT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,187,500
Market Cap $560M
Description
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...

Get notified when there are updates to the investment portfolio of Neuberger Berman Group LLC, based on Form 13F filings with the SEC.

Stay updated on Neuberger Berman Group LLC with notifications on news.